<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Publication:
Integrated modeling of digital-motor and clinician-reported outcomes using item response theory: towards powerful trials for rare neurological diseases

Loading...
Thumbnail Image

School / College / Institute

Item type:Organizational Unit,
SCHOOL OF MEDICINE
Upper Org Unit
Item type:Organizational Unit,
Item type:Organizational Unit,

Program

Organization Authors

Co-Authors

Hamdan, Alzahra

Traschuetz, Andreas

Beichert, Lukas

Chen, Xiaomei

Gagnon, Cynthia

van de Warrenburg, Bart P.

Santorelli, Filippo M.

Coarelli, Giulia

Horvath, Rita

Klebe, Stephan

Date

Language

Embargo Status

No

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Robust and highly sensitive outcomes are crucial for small trials in rare diseases. Combining different outcome types might improve sensitivity to identify disease severity and progression, yet innovative methodologies are scarce. Here we develop an Item Response Theory framework that allows integrated modeling of both continuous and categorical outcomes (ccIRT). With degenerative ataxias, a group of rare neurological coordination diseases, as a showcase, we developed a ccIRT model integrating two ataxia outcome types: a clinician-reported outcome (Scale for the Assessment and Rating of Ataxia; SARA; categorical data) and digital-motor outcomes for gait and limb coordination (continuous data). The ccIRT model leveraged data from 331 assessments from a natural history study for spastic ataxias. The model describes SARA items and digital-motor outcomes data as functions of a common underlying ataxia severity construct, evaluating 9 gait and 17 limb coordination digital-motor measures for their ability to add to SARA in estimating individual ataxia severity levels. Based on our proposed workflow for assessing digital-motor outcomes in ccIRT models, the final model selected three digital gait and three limb coordination measures, reducing average uncertainty in ataxia severity estimates by 49% (10% SD) compared to the SARA-only IRT model. Trial simulations showed a 49% and 61% reduction in sample sizes needed to detect disease-modifying effects in two genotypes. Overall, our ccIRT framework for combining multiple outcome domains, even of different variable types, facilitates a more precise estimation of disease severity and a higher power, which is particularly relevant for rare diseases with inherently small and short trials.Trial Registration: : NCT04297891

Source

Publisher

Wiley

Citation

item.page.haspartof

Source

CPT: Pharmacometrics and Systems Pharmacology

item.page.ispartofseries

item.page.edition

DOI

10.1002/psp4.70081

item.page.datauri

item.page.link

Rights

CC BY-NC (Attribution-NonCommercial)

Copyrights Note

Creative Commons license

Except where otherwise noted, this item's license is described as CC BY-NC (Attribution-NonCommercial)

Endorsement

Review

Supplemented By

Referenced By

Related Patent

Related Goal

Google Scholar
Scholar'da Ara ↗
Altmetric
Dimensions
PlumX Metrikleri
BIP! Indicators